Stem Cell-Based Regenerative Therapies for Ischemic Heart Disease: Mechanisms, Clinical Evidence, and Translational Strategies

Liu Hanxiang, Yijia Li, Huixian Zhou, Yixin Yang, Rongkai Yan, Xiaofeng Zhang, Yutong Miao, Siyuan Song and Lingyu Bao

AI Med, 2025, vol. 1, issue 2

Abstract: Ischemic heart disease (IHD) remains a major cause of global morbidity and mortality, with limited regenerative capacity of the adult myocardium posing a persistent therapeutic challenge. Stem cell-based interventions have emerged as a promising approach, offering the potential to restore cardiac function through angiogenesis, anti-fibrotic modulation, and tissue integration. This review comprehensively examines the therapeutic potential of three major cell types—induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs), mesenchymal stem cells (MSCs), and cardiac progenitor cells (CPCs)—in both preclinical and clinical settings. iPSC-CMs demonstrate direct cardiomyocyte replacement and promote neovascularization via the VEGF/PI3K/Akt pathway. MSCs act primarily through paracrine signaling, attenuating fibrosis and inflammation via TGF-β/Smad2/3 activation, while CPCs support myocardial survival and integration through Notch signaling. Clinical trials highlight moderate improvements in left ventricular function and quality of life, particularly with MSC and CPC therapies. However, challenges persist, including cell immaturity, immune rejection, limited engraftment, and inconsistent long-term efficacy. Future directions emphasize strategies to enhance cell maturation, reduce immunogenicity, and refine clinical trial design. Integration of bioengineering techniques, gene modification, and personalized therapeutic platforms may ultimately enable the safe and effective translation of stem cell therapies into routine care for patients with IHD.

Keywords: Ischemic heart disease; stem cell therapy; induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs); mesenchymal stem cells (MSCs); cardiac progenitor cells (CPCs); VEGF/PI3K/Akt pathway; TGF-β/Smad signaling; Notch pathway; cardiac regeneration; clinical translation (search for similar items in EconPapers)
Date: 2025
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.ai-press.org/index.php/aimed/article/view/10-71423-aimed-20250630 Abstract page (text/html)
https://www.ai-press.org/index.php/aimed/article/d ... 423-aimed-20250630/3 Full text (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:ayf:j00001:4

DOI: 10.71423/aimed.20250630

Access Statistics for this article

More articles in AI Med from AI Press Limited
Bibliographic data for series maintained by Ming Wu ().